Jose R Arribas

Summary

Country: Spain

Publications

  1. doi request reprint The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
    Jose R Arribas
    Hospital La Paz, Madrid, Spain
    AIDS 24:223-30. 2010
  2. doi request reprint The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline
    J R Arribas
    University Hospital La Paz, IdiPAZ, Madrid, Spain
    HIV Med 13:398-405. 2012
  3. pmc Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases
    Silvia García-Bujalance
    Department of Microbiology and Parasitology, La Paz University Hospital IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
    Malar J 11:136. 2012
  4. pmc Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 8:20. 2008
  5. ncbi request reprint [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker]
    José R Arribas López
    Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:23-7. 2008
  6. ncbi request reprint [Role of the new molecules in antiretroviral therapy. Position of raltegravir]
    Jose R Arribas
    Consulta de Medicina Interna II Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:53-9. 2008
  7. ncbi request reprint [The "induction-maintenance" strategy]
    José R Arribas López
    Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:8-11. 2008
  8. doi request reprint Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)
    Jose R Arribas
    Servicio de Medicina Interna, Unidad VIH Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    Curr Opin HIV AIDS 4:507-12. 2009
  9. ncbi request reprint Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine, Madrid, Spain
    J Acquir Immune Defic Syndr 35:343-50. 2004
  10. ncbi request reprint Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009

Collaborators

Detail Information

Publications31

  1. doi request reprint The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml
    Jose R Arribas
    Hospital La Paz, Madrid, Spain
    AIDS 24:223-30. 2010
    ..In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides...
  2. doi request reprint The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline
    J R Arribas
    University Hospital La Paz, IdiPAZ, Madrid, Spain
    HIV Med 13:398-405. 2012
    ..two nucleoside reverse transcriptase inhibitors (NRTIs) plus DRV/r at the primary 48-week analysis. The trial was continued to week 144 to assess the durability of the results...
  3. pmc Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases
    Silvia García-Bujalance
    Department of Microbiology and Parasitology, La Paz University Hospital IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain
    Malar J 11:136. 2012
    ..Factors like drug interactions and the possible implication of anti-malarial therapy bioavailability are all especially interesting in HIV-malaria co-infections...
  4. pmc Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    BMC Infect Dis 8:20. 2008
    ..The aim was to identify predictive markers of CD4+ cell count declines to < 350/microL in CD4-guided antiretroviral treatment interruptions...
  5. ncbi request reprint [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker]
    José R Arribas López
    Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:23-7. 2008
    ..However, long-term follow up is required on patients treated with to be able to rule out any increased susceptibility to infections or neoplasms...
  6. ncbi request reprint [Role of the new molecules in antiretroviral therapy. Position of raltegravir]
    Jose R Arribas
    Consulta de Medicina Interna II Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:53-9. 2008
    ..The drug's unusual mechanism of action has reopened the possibility of a positive effect on latent HIV reservoirs...
  7. ncbi request reprint [The "induction-maintenance" strategy]
    José R Arribas López
    Consulta de Medicina Interna II, Unidad VIH, Hospital La Paz, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:8-11. 2008
    ..However, rates of virological efficacy are lower than those achieved with the simplification strategy. Moreover, this trial demonstrates that LPV/r monotherapy may have major benefits in peripheral fat preservation...
  8. doi request reprint Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine)
    Jose R Arribas
    Servicio de Medicina Interna, Unidad VIH Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    Curr Opin HIV AIDS 4:507-12. 2009
    ..This review focuses on the use of tipranavir/ritonavir, darunavir/ritonavir and etravirine for the treatment of HIV infection that has become resistant to protease inhibitors and/or nonnucleoside reverse transcriptase inhibitors...
  9. ncbi request reprint Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Complutense University School of Medicine, Madrid, Spain
    J Acquir Immune Defic Syndr 35:343-50. 2004
    ..To compare the clinical, immunologic, and virologic outcomes of efavirenz (EFV)-based versus protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) in severely immunosuppressed HIV-1-infected patients...
  10. ncbi request reprint Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad VIH, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 14:195-201. 2009
    ..Risk factors for loss of virological response in patients receiving lopinavir/ritonavir (LPV/r) monotherapy as maintenance treatment have not been determined...
  11. ncbi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
    Federico Pulido
    Unidad HIV and Laboratorio de Microbiología Molecular, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    AIDS 22:F1-9. 2008
    ..Prior attempts to reduce the number of drugs needed to maintain viral suppression in patients with suppressed HIV replication while receiving three antiretroviral drugs have been unsuccessful...
  12. doi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
    Jose R Arribas
    Servicio de Medicina Interna, Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    J Acquir Immune Defic Syndr 51:147-52. 2009
    ..However, it is still uncertain if this experimental strategy can maintain suppression in the long term...
  13. doi request reprint Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
    Federico Pulido
    Unidad HIV, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    J Antimicrob Chemother 61:1359-61. 2008
    ..Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented...
  14. doi request reprint Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 47:1083-92. 2008
    ..The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials...
  15. doi request reprint Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy
    Federico Pulido
    HIV Unit, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain
    Antivir Ther 16:59-65. 2011
    ..When patients have HIV RNA suppressed to <50 copies/ml on current treatment, switching to darunavir (DRV)/ritonavir (DRV/r) monotherapy could prevent the development of resistance to other drug classes...
  16. doi request reprint Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption
    Elena Seoane
    Laboratorio de Inmuno Biología Molecular, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    J Acquir Immune Defic Syndr 48:455-9. 2008
    ..The aims of the present study were to determine if metabolic abnormalities and cytokine derangements are modified in HIV-1-infected patients after 12 months on treatment interruption (TI)...
  17. ncbi request reprint Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors
    Maria Luisa Montes
    Internal Medicine Service, La Paz Hospital, Autonoma University School of Medicine, Madrid, Spain
    J Antimicrob Chemother 55:800-4. 2005
    ..The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients...
  18. doi request reprint Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation?
    Miriam Estébanez
    HIV Unit, Internal Medicine Service bMicrobiology Service Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
    AIDS 27:141-4. 2013
    ..In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine...
  19. ncbi request reprint HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy
    José F Pascual-Pareja
    Servicio de Medicina Interna, Hospital La Paz, Paseo de la Castellana 261, Madrid 28046, Spain
    AIDS 23:971-5. 2009
    ..To evaluate the impact of HAART on the liver damage of HIV-hepatitis C virus (HCV)-coinfected patients with relatively preserved immune status...
  20. ncbi request reprint Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008
    ..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...
  21. ncbi request reprint Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)
    Jose R Arribas
    Hospital La Paz, Consulta de Medicina Interna II, Paseo de la Castellana, 28046 Madrid, Spain
    J Acquir Immune Defic Syndr 40:280-7. 2005
    ..This study evaluated maintenance with lopinavir/ritonavir monotherapy vs. continuing lopinavir/ritonavir and 2 nucleosides in HIV-infected patients with suppressed HIV replication...
  22. doi request reprint Protease inhibitor monotherapy
    Ignacio Pérez-Valero
    Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ Madrid, Spain
    Curr Opin Infect Dis 24:7-11. 2011
    ..The present review focuses on recent data about boosted protease inhibitor monotherapy for maintenance of HIV virological suppression...
  23. ncbi request reprint High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)
    Jose R Arribas
    Internal Medicine Service, La Paz Hospital, Autonoma University School of Medicine, Madrid, Spain
    AIDS 16:1554-6. 2002
    ..Efavirenz-based HAART was found to be effective in profoundly immunosuppressed HIV-1-infected patients...
  24. ncbi request reprint Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study
    Maria Jesús Pérez-Elías
    Infectious Diseases Service, Clinical Research Department, Ramon y Cajal Hospital, Madrid, Spain
    Antivir Ther 8:577-84. 2003
    ..Resistance testing is useful in the management of virological failure patients, although the best method to be used in clinical practice has not been determined...
  25. doi request reprint Protease inhibitor monotherapy: what is its role?
    Miriam Estébanez
    Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ, Madrid, Spain
    Curr HIV/AIDS Rep 9:179-85. 2012
    ..Some of the uncertainties possibly associated with protease inhibitor monotherapy such as the increased risk of neurological events and a higher level of subclinical inflammation will be discussed in this review...
  26. doi request reprint Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study
    María Luisa Montes Ramírez
    HIV Unit, Service of Internal Medicine, Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain Service of Infectious Diseases, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain Service of Infectious Diseases, Hospital Ramon y Cajal, Madrid, Spain HIV Clinical Unit, Internal Medicine Department and Fundació de la Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain Unit of Infectious Diseases, Hospital Donostia, Donostia San Sebastian, Spain Infectious Diseases and HIV Unit, Hospital General Universitario Gregorio Maranon, Instituto de Investigación Sanitaria Gregorio Marañón IiSGM, Madrid, Spain HIV Unit, Hospital 12 de Octubre and Universidad Europea de Madrid, Madrid, Spain Unit of Infectious Diseases, Hospital General Universitario de Valencia, Valencia, Spain and Service of Internal Medicine, Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain
    J Acquir Immune Defic Syndr 65:82-6. 2014
    ..2%, p < 0.06). ..
  27. pmc Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy
    Ignacio Pérez-Valero
    HIV Unit Internal Medicine Service, Hospital Universitario La Paz IdiPAZ, Madrid, Madrid, Spain
    PLoS ONE 8:e69493. 2013
    ....
  28. doi request reprint Protease inhibitor monotherapy and the CNS: peace of mind?
    Ignacio Pérez-Valero
    Servicio de Medicina Interna, Unidad VIH, Hospital La Paz, IdiPAZ, Madrid, Spain
    J Antimicrob Chemother 66:1954-62. 2011
    ..It is clear that more studies including detailed neurocognitive testing are needed to completely establish the risk/benefit ratio of bPI monotherapy or triple-drug HAART for preserving neurocognitive function in HIV-infected patients...
  29. doi request reprint Advances in antiretroviral therapy
    Jose R Arribas
    Servicio de Medicina Interna, Unidad VIH Hospital La Paz, IdiPAZ Madrid, Spain
    Curr Opin HIV AIDS 8:341-9. 2013
    ..To review recent data about advances in ART...
  30. ncbi request reprint Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan guidelines, 2004 [correction]
    Juan Berenguer
    Unidad de Enfermedades Infecciosas, Hospital General Gregorio Maranon, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:160-76. 2004
    ..To provide an update of guidelines from the Spanish AIDS Study Group (GESIDA) and the National AIDS Plan (PNS) committee on the prevention of opportunistic infections in adult and adolescent HIV-infected patients...
  31. doi request reprint Updating our understanding of pulmonary disease associated with HIV infection
    Miriam Estébanez-Muñoz
    Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, IdiPAZ, Madrid, Espana
    Arch Bronconeumol 48:126-32. 2012
    ..The aim of this paper is to review the most innovative and relevant aspects of lung pathology in patients infected with HIV...